Image Modified
ScopeScope |
This project team will create a White Paper with recommendations for Adverse Event Collection Instructions, with a focus on Phase 2-4 clinical trials. This project will |
will build upon a paper that outlines results from a survey on current practices, indicating variation that can likely be reduced. Recommendations will be based on the desired end-in-mind, and may or may not be consistent with current practices. |
| Project Leads | Emails |
|---|
Aimee Basile |
Nicola Newton, PHUSE Project |
| Status |
|---|
| colour | Blue |
|---|
| title | Current Status |
|---|
|
|
|---|
| The project scope has now been defined and the team are working through 'site feedback' to establish if this will be incorporated into their survey or not. |
|
|---|
- The AE collection white paper went out for public review – comments due 14 February.
|
| Objectives & Deliverables | Timelines |
| To create and prioritise a list of potential targets for where alignment would be beneficial | Q12021 |
| An initial version of a White Paper is planned to provide recommendations for some targets | Q42021 |
| Future planning - to have later versions to continue the journey of the process of improving Adverse Event Collection | Beyond 2021 |
| Project Members | Company |
|---|
| Alec Vardy | Jazzpharma |
| Andrea Rauch | Boehringer Ingelheim |
| Cathy Bezek | Astellas |
| Elisa Young | SouthernStarResearch |
| Jeannine Hughes | Boehringer Ingelheim |
| Jun Li | Sanofi |
| Kathy Taylor | Unither |
| Kim Musgrave | Amgen |
| Kit Howard | CDISC |
| Laura Goebel | Janssen Research & Development |
| Patrick Hannon | MMS |
| Pranab Mitra | Industry |
| Robin White | Eli Lilly |
| Tatiana Roberson | Unither |
| Publish White Paper | Q2 2024 |
William Palo | AbbVie